• Chen-Ti Wang, Che-Wei Chang, Yung-Chuan Lu, Hing-Chung Lam, Shu-Ju Ku, Kuo-Bin Tseng, and Yu-Hsi Kao.
• Division of Endocrinology and Metabolism, Department of Internal Medicine, E-Da Hospital/I-Shou University, No. 1, Yida Road, Kaohsiung City, 824, Taiwan.
• J Formos Med Assoc. 2020 Aug 1; 119 (8): 1325-1328.

AbstractSodium-glucose cotransporter-2 (SGLT-2) inhibitors have become the best choice of second-line oral antidiabetic drugs for patients with heart or chronic kidney disease. However, it is not clear how safe this treatment is for elderly patients, especially Asians, who are known to be more insulin deficient than Caucasian individuals with a similar insulin resistance. Here, we report a case concerning an elderly patient with type 2 diabetes mellitus without insulin dependence, whose antidiabetic medication had recently been changed to include an SGLT-2 inhibitor. The patient presented with an atypical hyperosmolar hyperglycemic state and diabetic ketoacidosis but recovered after insulin pump treatment and fluid supplementation. The patient was discharged with a prescription of a mixed-type insulin injection instead of oral antidiabetic medications for diabetes control. Our case demonstrates that if SGLT-2 inhibitors are administered to elderly Asian patients, their benefits and adverse effects should be carefully monitored.Copyright © 2019 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

18 keywords...

hide…